PubMed · 2000 · 39 citations · 0 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPulmonologySleep MedicineRespiratory MonitoringSleep Apnea CareSleep AssessmentSleep DisturbanceSleep-disordered BreathingSleep-related Breathing DisordersApnea-hypopnea Index ReductionObstructive Sleep Apnea TherapyObstructive Sleep Apnea TreatmentRepeated MeasurementsSleep Apnea MonitoringSleep Apnea SyndromeTheophylline Therapy
Theophylline has been recommended in the literature as a therapeutic option in mild OSAHS. In mild obstructive sleep apnea/hypopnea syndrome (OSAHS), night-to-night variability of parameters of sleep-disordered breathing has been determined rarely, we therefore compared the results of serial measurements of sleep apnea/hypopnea parameters under the effects of placebo and theophylline. To this end, we measured the individual variability of the apnea-hypopnea index (AHI) for seven consecutive nights using a portable sleep apnea recording device, in 14 subjects (2 women, 12 men, mean age +/- [standard deviation] 50 +/- 8 years), treated with placebo or theophylline in a double blind, randomized crossover fashion, whose polysomnographically measured AHI was 13 +/- 5 /hour. Under theophylline treatment in comparison with placebo we observed a small but significant decrease in mean (of seven days) AHI at home (9.2 +/- 7.7 to 6.7 +/- 6.1 /hour), which was independent of body position. The night-to-night variability of AHI at home was high (9. 2 +/- 8.9 /hour; range: 0-31.4 /hour) and proved to be independent of body position and alcohol consumption. - In mild OSAHS, repeated measurements of sleep related breathing events should be performed. Theophylline showed a small but clinically insignificant potencial to reduce AHI.